Vancouver, British Columbia – May 30, 2017 – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, Frankfurt:1N9) is pleased to announce that its joint venture subsidiary, Ambarii Trade Corporation (“Ambarii”) and Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) have entered into a LOI for the sale and distribution of Ambarii’s proprietary sublingual full spectrum hemp CBD tablets (“Ambarii CBD Tablets”) in Japan and South Korea.
Under the terms of the LOI, Ambarii will manufacture and supply Ambarii CBD Tablets to Naturally Splendid for exclusive distribution in Japan and South Korea. In addition to the revenue generated from product sales, Ambarii will also receive a royalty on all sales.
Ambarii CBD Tablets are quick dissolving and offer a metered dose of full spectrum hemp oil, combined with the powerful antioxidant properties of pterostilbene. The tablets will be flavor optimized for each national market with zero-sugar. Ambarii CBD Tablets represent a market first and the only commercially ready tablet of its kind.
Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. The company is building an expanding portfolio of patents and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.
NeutriSci’s President, Glen Rehman stated, “This agreement establishes the first product distribution deal for the newly formed Ambarii. Together with our joint venture partner, Lexaria Bioscience, we are very excited to have made such significant progress with Ambarii. This agreement represents a significant milestone in the cannabinoid industry as it represents the completion of the first ‘plant to blood stream’ product of its kind. We look forward to working with Naturally Splendid on this exciting new venture.”
To find out more about Ambarii, please visit www.ambariicorp.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
NeutriSci International Inc.
Tel: (403) 264-6320
For investor relations inquiries:
Skanderbeg Capital Advisors
O: 604‐687‐7130 x105
About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is currently focused on building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries. neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine. neuenergy® provides sustained energy and focus without sugar, calories, carbs or the jitters typically associated with energy products. For more information, visit: www.getneuenergy.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward- looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.